Biomx Stock News

Zacks Investment Research cut shares of BiomX (NYSEMKT:PHGE) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect []

Zacks Investment Research lowered shares of BiomX (NYSEMKT:PHGE) from a buy rating to a hold rating in a report published on Wednesday, Zacks.com reports. According to Zacks, BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance []

BiomX (NYSEMKT:PHGE) issued its earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.31) by ($0.06), MarketWatch Earnings reports. Shares of BiomX stock traded down $0.12 during trading hours on Tuesday, reaching $2.37. 183,316 shares of the stock traded hands, compared to its average []

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q3 2021 Results - Earnings Call Transcript

Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022

Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022

BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects.  A statistically significant improvement from baseline was o

12-Week Study of BX001 Meets Safety and Tolerability Endpoints

BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natur

Utilizing its proprietary BOLT and synthetic biology platforms, BiomX develops natural and engineered phage therapeutic cocktails to treat chronic diseases ranging from acne, IBD, PSC, CF, A. Dermatit

BiomX, Inc. designs species-specific phage cocktails to neutralize bacteria prevalent in many disease types.

BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natu

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2021 Results - Earnings Call Transcript

Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023

NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered ph